| Literature DB >> 25834119 |
Erin M Kropp1, Bryndon J Oleson1, Katarzyna A Broniowska1, Subarna Bhattacharya1, Alexandra C Chadwick1, Anne R Diers1, Qinghui Hu1, Daisy Sahoo1, Neil Hogg1, Kenneth R Boheler1, John A Corbett1, Rebekah L Gundry2.
Abstract
The tumorigenic potential of human pluripotent stem cells (hPSCs) is a major limitation to the widespread use of hPSC derivatives in the clinic. Here, we demonstrate that the small molecule STF-31 is effective at eliminating undifferentiated hPSCs across a broad range of cell culture conditions with important advantages over previously described methods that target metabolic processes. Although STF-31 was originally described as an inhibitor of glucose transporter 1, these data support the reclassification of STF-31 as a specific NAD⁺ salvage pathway inhibitor through the inhibition of nicotinamide phosphoribosyltransferase (NAMPT). These findings demonstrate the importance of an NAD⁺ salvage pathway in hPSC biology and describe how inhibition of NAMPT can effectively eliminate hPSCs from culture. These results will advance and accelerate the development of safe, clinically relevant hPSC-derived cell-based therapies. ©AlphaMed Press.Entities:
Keywords: Human pluripotent stem cells; Metabolism; NAD; Salvage pathway; Selective toxicity
Mesh:
Substances:
Year: 2015 PMID: 25834119 PMCID: PMC4414215 DOI: 10.5966/sctm.2014-0163
Source DB: PubMed Journal: Stem Cells Transl Med ISSN: 2157-6564 Impact factor: 6.940